Brief: Optinose Reports Q3 2022 Financial Results

OptiNose

10/11/2022 12:39

Nov 10 (Reuters) - Optinose Inc  OPTN.O :
    * OPTINOSE REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND
OPERATIONAL UPDATES
    * COMPANY PLANS TO SUBMIT AN SNDA FOR XHANCE AS A TREATMENT
FOR
CHRONIC SINUSITIS IN EARLY 2023
    * EXPECTS FULL YEAR 2022 XHANCE NET REVENUE TO BE BETWEEN
$74 TO
$78 MILLION
    * CASH AND CASH EQUIVALENTS OF $61.1 MILLION AS OF SEPTEMBER
30,
2022
    * QTRLY LOSS PER SHARE $0.18
    * Q3 EARNINGS PER SHARE VIEW $-0.19 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX744wqR 
Further company coverage:  OPTN.O 
 ((Reuters.Briefs@thomsonreuters.com;))